======= RNASEH2A =======
== Gene Information ==
* **Official Symbol**: RNASEH2A
* **Official Name**: ribonuclease H2 subunit A
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10535|10535]]
* **UniProt**: [[https://www.uniprot.org/uniprot/O75792|O75792]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=RNASEH2A&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20RNASEH2A|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/606034|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: The protein encoded by this gene is a component of the heterotrimeric type II ribonuclease H enzyme (RNAseH2). RNAseH2 is the major source of ribonuclease H activity in mammalian cells and endonucleolytically cleaves ribonucleotides. It is predicted to remove Okazaki fragment RNA primers during lagging strand DNA synthesis and to excise single ribonucleotides from DNA-DNA duplexes. Mutations in this gene cause Aicardi-Goutieres Syndrome (AGS), a an autosomal recessive neurological disorder characterized by progressive microcephaly and psychomotor retardation, intracranial calcifications, elevated levels of interferon-alpha and white blood cells in the cerebrospinal fluid.[provided by RefSeq, Aug 2009].
* **UniProt Summary**: Catalytic subunit of RNase HII, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging- strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes. {ECO:0000269|PubMed:16845400, ECO:0000269|PubMed:21177858}.
|RNase HII|
|ribonuclease H2 complex|
|DNA replication, removal of RNA primer|
|RNA-DNA hybrid ribonuclease activity|
|ribonuclease activity|
|mismatch repair|
|RNA phosphodiester bond hydrolysis, endonucleolytic|
|RNA phosphodiester bond hydrolysis|
|DNA replication|
|RNA catabolic process|
|nucleic acid phosphodiester bond hydrolysis|
|nucleobase-containing compound catabolic process|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|organic cyclic compound catabolic process|
|DNA repair|
|DNA metabolic process|
|cellular response to DNA damage stimulus|
|cellular macromolecule catabolic process|
|macromolecule catabolic process|
|RNA binding|
|RNA metabolic process|
|cellular response to stress|
|cellular macromolecule biosynthetic process|
|macromolecule biosynthetic process|
|organic substance catabolic process|
|cellular catabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-3.52|
|[[:results:exp147|Resveratrol 16μM R03 exp147]]|-2.87|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|-2.61|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|-2.49|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-2.4|
|[[:results:exp270|Campthothecin 0.001μM R06 exp270]]|-2.26|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-2.26|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-2.2|
|[[:results:exp278|CVT-10216 0.1μM R06 exp278]]|-2.18|
|[[:results:exp78|Pterostilbene 16μM R02 exp78]]|-2.12|
|[[:results:exp185|L-BMAA 500 to 750μM on day4 R04 exp185]]|-2.09|
|[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|-2.08|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-2.08|
|[[:results:exp340|BN82002 4μM R07 exp340]]|-2.02|
|[[:results:exp245|UM0011500 5μM R05 exp245]]|-2|
|[[:results:exp180|Dynasore 10μM R04 exp180]]|-1.95|
|[[:results:exp464|Calcipotriol 5μM R08 exp464]]|-1.9|
|[[:results:exp379|MSC2530818 10μM R07 exp379]]|-1.86|
|[[:results:exp262|Alda-1 10μM R06 exp262]]|-1.82|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-1.81|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-1.74|
|[[:results:exp452|Azithromycin 100μM R08 exp452]]|1.85|
|[[:results:exp285|GW501516 25μM R06 exp285]]|2.09|
|[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|2.1|
|[[:results:exp449|Arsenic trioxide 60μM R08 exp449]]|2.5|
^Gene^Correlation^
|[[:human genes:r:rnaseh2b|RNASEH2B]]|0.52|
|[[:human genes:r:rnaseh2c|RNASEH2C]]|0.512|
|[[:human genes:k:kpna4|KPNA4]]|0.508|
|[[:human genes:s:spr|SPR]]|0.411|
Global Fraction of Cell Lines Where Essential: 8/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|1/33|
|central nervous system|1/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|1/75|
|lymphocyte|0/16|
|ovary|1/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|1/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3229
* **Expression level (log2 read counts)**: 5.61
{{:chemogenomics:nalm6 dist.png?nolink |}}